Schrodinger Q1 Revenue Beats Estimates, Drug Discovery Revenue Doubles
SDGR is trading near its 52-week low of $10.945 (6.9% above the low).
Summary
Schrodinger reported Q1 revenue of $58.59 million, significantly beating analyst estimates of $48.003 million, despite a 2% year-over-year decline. The overall revenue fall was attributed to a planned 21% decrease in software revenue due to an accelerated transition to hosted licensing, which was offset by drug discovery revenue more than doubling. The company also maintained its 2026 ACV guidance, projecting a 10-15% increase over 2025. This strong beat on revenue and robust growth in the drug discovery segment, a key strategic area, indicates underlying operational strength and successful execution of its business model transition, which is likely to be viewed favorably by investors. Traders will be watching the continued progress of the software licensing transition and further developments in its drug discovery collaborations.
At the time of this announcement, SDGR was trading at $11.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $950.1M. The 52-week trading range was $10.95 to $27.63. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.